Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?

eISSN: 1731-2515
ISSN: 0209-1712

Anestezjologia Intensywna Terapia

Current issue Archive About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

4/2019
vol. 51

Send email

Copy url:

abstract:

Review article

Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?

Anestezjologia Intensywna Terapia
2019; 51, 4: 305–311

Online publish date: 2020/01/23

View full text Get citation

Sepsis is a life-threatening organ dysfunction caused by a systemic altered host response to infection. According to the newest guidelines the sepsis treatment should be personalized and based on an approach specified by use of biomarkers to tailor therapy to each patient’s needs. The main features of such biomarkers should be high specificity, sensitivity and ability to monitor the progress of sepsis. There is limited application of procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6) for reaching this target, because of their secretion during non-infectious processes. The purpose of this review was to introduce four biomarkers, i.e. kallistatin, testican-1, presepsin and mid-regional pro-adrenomedullin, and compare their usefulness in diagnosing sepsis with PCT, CRP and IL-6.

keywords:

Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?

sepsis, biomarkers, monitoring, mortality